Cargando…
Integrating Xpert MTB/RIF for TB diagnosis in the private sector: evidence from large-scale pilots in Patna and Mumbai, India
BACKGROUND: Xpert MTB/RIF (Xpert) has been recommended by WHO as the initial diagnostic test for TB and rifampicin-resistance detection. Existing evidence regarding its uptake is limited to public health systems and corresponding resource and infrastructure challenges. It cannot be readily extended...
Autores principales: | Deo, Sarang, Jindal, Pankaj, Papineni, Sirisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844908/ https://www.ncbi.nlm.nih.gov/pubmed/33509114 http://dx.doi.org/10.1186/s12879-021-05817-1 |
Ejemplares similares
-
New TB Tools Need to be Affordable in the Private Sector: The Case Study of Xpert MTB/RIF
por: Ponnudurai, Nirros, et al.
Publicado: (2018) -
Contribution of Xpert(®) MTB/RIF to pediatric TB diagnosis in Mozambique
por: Mutemba, C. M., et al.
Publicado: (2023) -
Using Xpert MTB/RIF
por: Nicol, Mark P., et al.
Publicado: (2013) -
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
por: Horne, David J, et al.
Publicado: (2019) -
Upfront Xpert MTB/RIF for diagnosis of pediatric TB—Does it work? Experience from India
por: Kalra, Aakshi, et al.
Publicado: (2020)